News | Radiation Therapy | September 22, 2016

Company will introduce Hyperscan with new adaptive aperture technology allowing faster, sharper and robust pencil beam scanning

Mevion, Hyperscan with Adaptive Aperture, intensity modualted proton therapy, IMPT, ASTRO 2016

September 22, 2016 — Mevion Medical Systems will showcase its pencil beam scanning Hyperscan with Adaptive Aperture at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 25-28 in Boston. The advanced proton micro-multileaf collimator (mMLC) technology is integrated into the Mevion S250i with Hyperscan, making pencil beam scanning sharper and faster and delivering robust intensity modulated proton therapy (IMPT).

Hyperscan with Adaptive Aperture delivers a pencil beam that is up to 50 times faster and 3 times sharper than conventional systems used for IMPT, and can scan a typical lung tumor in less than two seconds. The technology includes a low-profile mMLC system designed specifically for pencil beam scanning that is capable of delivering the sharpest penumbra physically achievable with protons without the need for manual apertures and adjustments, according to Mevion. Its novel layer-by-layer specific beam collimation and blocking achieves 1-3mm collimated spot sizes, for all energies, at any depth.

James Cooley, senior accelerator engineer at Mevion said the new technology is ideal for treating pediatric tumors or shallow brain tumors where small spot sizes have been difficult to achieve by conventional systems.

Mevion is also announcing the growth of its leadership team. The expansion includes the hiring of three industry experts and two internal moves:

  • Yoel Bakas, vice president of sales, Americas, joins Mevion from Varian Medical Systems, where he oversaw strategic account development and has focused on medical devices sales for the past 17 years;
  • Scott Soehl, vice president of international sales, joins Mevion with more than 35 years of radiation oncology experience, having previously worked at Elekta and IMPAC Medical Systems;
  • Curt Kienast, vice president of global services, is promoted from within Mevion where he previously served as senior director of product development. Curt has more than 15 years of experience in healthcare quality and services;
  • Chris Dodge, field vice president, The Americas; business development & customer financing, joins Mevion with 30 years of medical device sales and marketing experience, having previously worked at Varian Medical Systems for the past 15 years; and
  • George Rugg, vice president of business development, is appointed from his previous position as Mevion’s vice president of global services. George’s career spans 30 years of working in the oncology field.

For more information: www.mevion.com


Related Content

News | Women's Health

May 6, 2026 — GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT2, a solution designed to ...

Time May 06, 2026
arrow
News | Radiation Oncology

April 27, 2026 — Radiation oncologists from across the country were in Washington in late April to warn lawmakers that ...

Time May 04, 2026
arrow
News | Radiation Therapy

April 30, 2026 — The Siemens Healthineers business area, Varian, has been awarded up to $60 million over five years by ...

Time April 30, 2026
arrow
News | Radiology Business

April 10, 2026 — The radiation therapy team at The Ohio State University Wexner Medical Center, The James Cancer ...

Time April 10, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
Subscribe Now